Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease

Cell Transplantation

Volumn 9, Issue 2, 2000, Pages 215-221

  Benazzouz, A ^a   Piallat, B ^a   Ni, Z G ^a   Koudsie, A ^a   Pollak, P ^a   Benabid, A L ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

High frequency stimulation; Neuroprotection; Parkinson's disease; Subthalamic nucleus

Indexed keywords

DOPAMINE; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; OXIDOPAMINE;

ANIMAL MODEL; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STIMULATION; SUBTHALAMIC NUCLEUS;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 0034067019     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.1177/096368970000900207     Document Type: Article

References (87)

1. Alexander, G. E.; Crutcher, M. D. Functional architecture of basal ganglia circuits: Neural substractes of parallel processing. Trends Neurosci. 13:266-271; 1990.
2. Aziz, T. Z.; Peggs, D.; Sambrook, M. A.; Crossman, A. R. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 6: 169-173; 1991.
3. Baunez, C.; Nieoullon, A.; Amalric, M. In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit. J. Neurosci. 15:6531-6541; 1995.
4. Baunez, C.; Robbins, T. W. Bilateral lesions of the subthalamic nucleus induce multiple deficits in an attentional task in rats. Eur. J. Neurosci. 9:2086-2099; 1997.
5. Beckman, J. S.; Beckman, T. W.; Chen, J.; Marshall, P. A.; Freeman, B. A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxyde. Proc. Natl. Acad. Sci. USA 87:1620-1624; 1990.
6. Benabid, A. L.; Pollak, P.; Gervason, C. L.; Hoffmann, D.; Gao, D. M.; Hommel, M.; Perret, J. E.; De Rougemont, J. Long term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337:403-406; 1991.
7. Benabid, A. L.; Pollak, P.; Gao, D. M.; Hoffmann, D.; Limousin, P.; Gay, E.; Payen, I.; Benazzouz, A. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J. Neurosurg. 84:203-214; 1996.
8. Benabid, A. L.; Pollak, P.; Gross, Ch.; Hoffmann, D.; Benazzouz, A.; Gao, D. M.; Laurent, A.; Gentil, M.; Perret, J. Acute and long term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact. Funct. Neurosurg. 62:76-84; 1994.
9. Benabid, A. L.; Pollak, P.; Louveau, A.; Heunry, S.; De Rougement, J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson's disease. Appl. Neurophysiol. 30:344-346; 1987.
10. Bénavidès, J.; Camelin, J. C.; Mitrani, N.; Flamant, F.; Uzan, A.; Legrand, J. J.; Gueremy, C.; Le Fur, G. 2-amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino-acid neurotransmission. II. Biochemical properties. Neuropharmacology 24:1085; 1985.
11. Benazzouz, A.; Boraud, Th.; Dubédat, P.; Boireau, A.; Stutzmann, J. M.; Bioulac, B.; Gross, Ch. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A pilot study. Eur. J. Pharmacol. 284:299-307; 1995.
12. Benazzouz, A.; Gross, C.; Dupont, J.; Bioulac, B. MPTP induced hemiparkinsonism in monkeys: Behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp. Brain Res. 90:116-120; 1992.
13. Benazzouz, A.; Boraud, Th.; Féger, J.; Burbaud, P.; Bioulac, B.; Gross, Ch. Alleviation of experimental hemiparkinsonism by high frequency stimulation of the subthalamic nucleus in primate: A comparison with L-dopa treatment. Mov. Disord. 11:627-632; 1996.
14. Benazzouz, A.; Gross, C.; Féger, J.; Boraud, T.; Bioulac, B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 5:382-389; 1993.
15. Benazzouz, A.; Piallat, B.; Pollak, P.; Benabid, A. L. Responses of substantial nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: Electrophysiological data. Neurosci. Lett. 189:77-80; 1995.
16. Bergman, H.; Wichmann, T.; Delong, M. R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438; 1990.
17. Bergman, H.; Wichmann, T.; Karmon, B.; DeLong, M. R. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72: 507-520; 1994.
18. Boireau, A.; Miquet, J. M.; Dubédat, M.; Meunier, M.; Doble, A. Riluzole and experimental parkinsonism: Partial antagonism of MPP-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 5:2157-2163; 1994.
19. Boireau, A.; Dubédat, M.; Bordier, F.; Peny, C.; Miquet, J. M.; Durand, M. Meunier, M. Riluzole and experimental parkinsonism: Antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 5:2657-2663; 1994.
20. Brotchie, J. M.; Sambrook, M. A.; Mitchell, I. J.; Crossman, A. R. Alleviation of parkinsonism by antagonism of excitatory amino-acid transmission in the medial segment of the globus pallidus in rat and primate. Mov. Disord. 6: 133-138; 1991.
21. Burbaud, P.; Gross, C.; Benazzouz, A.; Coussemacq, M.; Bioulac, B. Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Exp. Brain Res. 105:48-58; 1995.
22. Buruma, O. J. S.; Lakke, J. P. W. F. Ballism. In: Vinken, P. J.; Bruyn, G. W.; Klawans, H. L., eds, The handbook of clinical neurology. Amsterdam: Elsevier; 1986:369-380.
23. Campbell, G. A.; Eckardt, M. J.; Weight, F. F. Dopaminergic mechanisms in subthalamic nucleus of rat: Analysis using horseradish peroxidase and microiontophoresis. Brain Res. 333:261-271; 1985.
24. Chergui, K.; Charléty, P.; Akaoka, H.; Saunier, C. F.; Brunet, J. L.; Buda, M.; Svensson, T. H.; Chouvet, G. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur. J. Neurosci. 5:137-144; 1993.
25. Chergui, K.; Suaud-Chagny, M. F.; Gonon, F. Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 62(3):641-645; 1994.
26. Crossman, A. R.; Sambrook, M. A.; Jackson, A. Experimental hemichorea/hemiballismus in the monkey. Studies of the intracerebral site of action in a drug induced dyskinesia. Brain 107:579-596; 1984.
27. Dawson, V. L.; Dawson, T. M.; London, E. D.; Bredt, D. S.; Snyder, S. H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88:6368-6371; 1991.
28. Filion, M.; Tremblay, L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547:142-151; 1991.
29. Gao, D. M.; Benazzouz, A.; Bressand, K.; Piallat, B.; Benabid, A. L. Roles of GABA, glutamate, acetylcholine and STN stimulation on thalamic VM in rats. Neuroreport 8:2601-2605; 1997.
30. Gao, D. M.; Benazzouz, A.; Piallat, B.; Bressand, K.; Ilinsky, I.; Kultas-Ilinsky, K.; Benabid A. F. High frequency stimulation of the subthalamic nucleus suppresses rest tremor in the monkey. Neuroscience 88:201-212; 1999.
31. Graham, W. C.; Robertson, R. G.; Sambrook, M. A.; Crossman, A. R. Injection of exciotatory amino-acid antagonists into the pallidal segment of the MPTP-treated primate reverses motor symptoms of parkinsonism. Life Sci. 47:91-97; 1990.
32. Guridi, J.; Herrero, M. T.; Luquin, M. R.; Guillen, J.; Ruberg, M.; Laguna, J.; Vila, M.; Javoy-Agid, F.; Agid, Y.; Hirsh, E.; Obeso, J. A. Subthalamotomy in parkinsonian monkeys, behavioral and biochemical analysis. Brain 119:1717-1727; 1996.
33. Hassani, O. K.; Mouroux, M.; Feger, J. Increased subthalamic neuronal activity after nigral dompaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 72:105-115; 1996.
34. Hamanda, I.; Delong, M. R. Excitotoxic acid lesions of the primate subthlamic nucleus result in reduced pallidal neuronal activity during active holding. J. Neurophysiol. 68:1859-1866; 1992.
35. Hammond, C.; Deniau, J. M.; Rizk, A.; Feger, J. Electrophysiological demonstration of an excitatory subthalamonigral pathway in the rat. Brain Res. 151:235-244; 1978.
36. Hammond, C.; Féger, J.; Bioulac, B.; Souteyrand, J. P. Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii. Brain Res. 171:577-580; 1979.
37. Hattori, N.; Tanka, M.; Ozawa, T.; Mizuno, Y. Immunohistological studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30:563-571; 1991.
38. Henderson, M.; Annett, L. E.; Torres, E. M.; Dunnett, S. B. Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus). Eur. J. Neurosci. 10:689-698; 1998.
39. Herrero, M. T.; Levy, R.; Ruberg, M.; Luquin, M. R.; Villares, J.; Guillen, J., Faucheux, B. Javoy-Agid, F.; Guridi, J.; Agid, Y.; Obeso, J. A.; Hirsch, E. C. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 47:219-224; 1996.
40. Hollerman, J. R.; Grace, A. A. Subthalamic nucleus cell firing in the 6-OHDA-treated rat: Basal activity and response to haloperidol. Brain Res. 590:291-299; 1992.
41. Ikebe, S.; Tanaka, M.; Ozawa, T. Point mutations of mitochondrial genome in Parkinson's disease. Mol. Brain Res. 28:281-295; 1995.
42. Ikebe, S.; Tanaka, M.; Ohno, K.; Sato, W.; Hattori, K.; Kondo, T.; Mizumo, Y.; Ozawa, T. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem. Biophys. Res. Commun. 170: 1044-1048; 1990.
43. Kitai, S. T.; Deniau, J. M. Cortical inputs to the subthalamus: Intracellular analysis. Brain Res. 214:411-415; 1987.
44. Krack, P.; Benazzouz, A.; Pollak, P.; Limousin, P.; Piallat, B.; Hoffmann, D.; Xie, J.; Benabid, A. L. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov. Disord. 13:907-914; 1998.
45. Krack, P.; Pollak, P.; Limousin, P.; Benazzouz, A.; Benabid, A. L. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. Lancet 350:1675; 1997.
46. Künzle, H. Projections from the primary somatosensory cortex to basal ganglia and thalamus in monkey. Exp. Brain Res. 30:481-492; 1977.
47. Kupsch, A.; Löschmann, P. A.; Sauer, H.; Arnold, G.; Renner, P.; Pufal, D.; Burg, M.; Watchel, H.; Bruggencate, G.; Oertel, W. H. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 592:74-83; 1992.
48. Lange, K. W.; Löschmann, P. A.; Sofic, E.; Burg, M.; Horowski, R.; Kalveram, K. T.; Watchel, H.; Riederer, P. The competitive NMDA antagonist CPP protects substantia nigra from MPTP-induced degeneration in primates. Arch. Pharmacol. 348:586-592; 1993.
49. Limousin, P.; Greene, J.; Pollak, P.; Rothwell, J.; Benabid, A. L.; Frackowiak, R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann. Neurol. 42:283-291; 1997.
50. Limousin, P.; Krack, P.; Pollak, P.; Benazzouz, A.; Ardouin, C.; Hoffmann, D.; Benabid, A. L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339:1105-1111; 1998.
51. Limousin, P.; Pollak, P.; Benazzouz, A.; Hoffmann, D.; Le Bas, J. F.; Broussolle, J. E.; Perret, J. E.; Benabid, A. L. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91-95; 1995.
52. Limousin, P.; Pollak, P.; Benazzouz, A.; Hoffmann, D.; Broussolle, J. E.; Perret, J.; Benabid, A. L. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov. Disord. 10:672-674; 1995.
53. Löschmann, P. A.; Lange, K. W.; Watchel, H.; Turski, L. MPTP-induced degeneration: Interference with glutamatergic toxicity. J. Neural Transm. Suppl. 43:133-143; 1994.
54. Martin, J. P. Hemichorea resulting from a local lesion of the brain: The syndrome of the body of Luys. Brain 50: 637-651; 1927.
55. Martin, D.; Thompson, M. A.; Nadler, J. V. The neuroprotective agent riluzole inhibits release of L-glutamate and L-aspartate from slices of hippocampal area CA1. Br. J. Pharmacol. 104:240-248; 1991.
56. Meibach, M. R. C.; Katzman, R. Catecholaminergic innervation of the subthalamic nucleus: Evidence for a rostral continuation of A9 (substantia nigra) dopaminergic group. Brain Res. 173:364-368; 1979.
57. Meyers, R. Ballismus. In: Vinken, P. J.; Bruyn, G. W., eds. The handbook of clinical neurology. Amsterdam: North-Holland Press; 1968:476-490.
58. Miller, W. C.; De Long, M. R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter, M. B.; Jayaraman, A., eds. The basal ganglia II. New York: Plenum Press; 1987:415-427.
59. Mintz, I.; Hammond, C.; Guibert, B.; Leviel, V. Stimulation of the subthalamic nucleus enhances the release of dopamine in the rat substantia nigra. Brain Res. 376:406-408; 1986.
60. Mitchell, I. J.; Clarke, C. E.; Boyce, S.; Robertson, R. G.; Peggs, D.; Sambrook, M. A.; Crossman, A. R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 32:213-226; 1989.
61. Mouroux, M.; Hassani, O. K.; Féger, J. Electrophysiological study of the excitatory parafascicular projection to the subthalamic nucleus and evidence for ipsi- and contralateral controls. Neuroscience 4:613-615; 1995.
62. Novelli, A.; Reilly, J. A.; Lysko, P. G.; Henneberry, R. C. Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels are reduced. Brain Res. 451:205-212; 1987.
63. O'Dell, S. J.; Weihmuller, F. B.; Marshall, J. F. MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow. In: Neurotoxins and neurodegenerative disease. Ann. NY Acad. Sci. 648:317-319; 1992.
64. Ohye, C.; Shibazaki, T.; Hirai, T.; Wada, H.; Kawashima, Y. Further physiological observations on the ventralis intermedius neurons in the human thalamus. J. Neurophysiol. 61:488-500; 1989.
65. Orrenius, S.; Nicotera, P. The calcium ion and cell death. J. Neural Transm. Suppl. 43:1-11; 1994.
66. Parent, A.; Hazrati, L. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20: 128-154; 1995.
67. Parker, W. D.; Boyson, S. J.; Parks, J. K. Abnormality of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:719-723; 1989.
68. Piallat, B.; Benazzouz, A.; Benabid, A. L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioral and immunohistochemical studies. Eur. J. Neurosci. 8: 1408-1414:\; 1996.
69. Piallat, B.; Benazzouz, A.; Benabid, A. L., Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. J. Neural Transm. Suppl. 55:71-77; 1999.
70. Robledo, P.; Féger, J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: Electrophysiological data. Brain Res. 518:47-54; 1990.
71. Rouzaire-Dubois, B.; Scarnati, E. Bilateral corticosubthalamic nucleus projections: An electrophysiological study in rats with chronic cerebral lesions. Neuroscience 15:69-79; 1985.
72. Saji, M.; Blau, A. D.; Volpe, B. T. Prevention of transneuronal degeneration of neurons in the substantia nigra reticulata by ablation of the subthalamic nucleus. Exp. Neurol. 141(1): 120-129; 1996.
73. Sauer, H.; Oertel, W. H. Progressive degeneration of nigrostriatral dopamine neurons following intrastriatal terminal lesions with 6-OHDA: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415; 1994.
74. Schapira, A. H. V. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov. Disord. 9:125-138; 1994.
75. Smith, Y.; Charara, A.; Parent. A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J. Comp. Neurol. 364: 231-253; 1996.
76. Smith, Y.; Grace, A. A. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 12:287-303; 1992.
77. Smith, Y.; Parent. A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 453:353-356; 1988.
78. Sonsalla, P. K.; Nicklas, W. J.; Heikkila, R. E. Role for excitatory amino acids in methamphetamine induced nigrostriatal dopaminergic toxicity. Science 243:398-400; 1989.
79. Sonsalla, P. K.; Riordan, D. H.; Heikkila, R. H. Competitive and non competitive antagonists at NMDA receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256:506-512; 1991.
80. Storey, E.; Hyman, B. T.; Jenkins, B.; Bouillet, E.; Miller, J. M.; Rosen, B. R.; Beal, F. M. MPP+ produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58:1975-1978; 1992.
81. Tasker, R. R.; Siqueira, J.; Hawrylyshyn, P.; Organ, L. W. What happened to VIM thalamotomy for Parkinson's disease. Appl. Neurophysiol. 46:68-83; 1983.
82. Tremblay, L.; Filion, M.; Bedard, P. J. Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism. Brain Res. 498:17-33; 1989.
83. Turski, L.; Bressler, K.; Rettig, K. J.; Löschmann, P. A.; Watchel, H. Protection of substantia nigra from MPP+ neurotoxicity by NMDA antagonists. Nature 349:414-418; 1991.
84. Vila, M.; Levy, R.; Herrero, M. T.; Ruberg, M.; Faucheux, B.; Obeso, J. A.; Agid, Y.; Hirsch, E. C. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and non-human primates: An in situ hybridization study of cytochrome oxydase subunit 1 mRNA. J. Neurosci. 17:765-773; 1997.
85. Whittier, J. R. Ballism and the subthalamic nucleus (nucleus hypothalamicus, corps Luysi). Arch. Neurol. Psychiatry 58:672-692; 1947.
86. Whittier, J. R.; Mettler, F. A. Studies of the subthalamus of the rhesus monkey. II. Hyperkinesia and other physiologic effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys. J. Comp. Neurol. 90: 319-372; 1949.
87. Zuddas, A.; Oberto, G.; Vaglini, F.; Fascetti, F.; Fornai, F.; Corsini, G. U. MK-801 prevents MPTP-induced parkisonism in primates. J. Neurochem. 59:733-739; 1992.